Josep M ArgilÃ©s

List of Publications by Year
in descending order

191 papers	16,340 citations	18482 62 h-index	17592 121 g-index
195 all docs	195 docs citations	195 times ranked	14032 citing authors

#	Article	IF	Citations
1	Cachexia: A new definition. Clinical Nutrition, 2008, 27, 793-799.	5.0	1,906
2	Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) â€œcachexia-anorexia in chronic wasting diseasesâ€•and â€œnutrition in geriatricsâ€• Clinical Nutrition, 2010, 29, 154-159.	5.0	1,360
3	Cancer cachexia: understanding the molecular basis. Nature Reviews Cancer, 2014, 14, 754-762.	28.4	991
4	Sarcopenia With Limited Mobility: An International Consensus. Journal of the American Medical Directors Association, 2011, 12, 403-409.	2.5	884
5	Nutritional Recommendations for the Management of Sarcopenia. Journal of the American Medical Directors Association, 2010, 11, 391-396.	2.5	548
6	Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease. Journal of the American Medical Directors Association, 2016, 17, 789-796.	2.5	317
7	Resveratrol, a Natural Product Present in Wine, Decreases Tumour Growth in a Rat Tumour Model. Biochemical and Biophysical Research Communications, 1999, 254, 739-743.	2.1	246
8	Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology, 2015, 22, 100-106.	3.5	231
9	Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E191-E202.	3.5	208
10	Inter-tissue communication in cancer cachexia. Nature Reviews Endocrinology, 2019, 15, 9-20.	9.6	191
11	Overexpression of Interleukin-15 Induces Skeletal Muscle Hypertrophy in Vitro: Implications for Treatment of Muscle Wasting Disorders. Experimental Cell Research, 2002, 280, 55-63.	2.6	186
12	The role of cytokines in cancer cachexia. , 1999, 19, 223-248.		183
13	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	2.2	167
14	Cross-talk between skeletal muscle and adipose tissue: A link with obesity?. Medicinal Research Reviews, 2005, 25, 49-65.	10.5	162
15	The role of cytokines in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2009, 3, 263-268.	1.3	162
16	TNF Can Directly Induce the Expression of Ubiquitin-Dependent Proteolytic System in Rat Soleus Muscles. Biochemical and Biophysical Research Communications, 1997, 230, 238-241.	2.1	159
17	Reduced Muscle Redox Capacity after Endurance Training in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1114-1118.	5.6	158
18	IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R674-R683.	1.8	149

#	Article	IF	Citations
19	Anticachectic Effects of Formoterol. Cancer Research, 2004, 64, 6725-6731.	0.9	148
20	Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: Evidence for a skeletal muscle-to-fat signaling pathway. Cell Biology International, 2005, 29, 449-457.	3.0	148
21	The metabolic basis of cancer cachexia. , 1997, 17, 477-498.		146
22	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 17-24.	2.4	146
23	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. International Journal of Biochemistry and Cell Biology, 2005, 37, 1084-1104.	2.8	144
24	Increased tumour necrosis factorâ€Î± plasma levels during moderate-intensity exercise in COPD patients. European Respiratory Journal, 2003, 21, 789-794.	6.7	143
25	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 87-93.	7.3	138
26	Consensus on Cachexia Definitions. Journal of the American Medical Directors Association, 2010, 11, 229-230.	2.5	134
27	Metabolic Effects of Tumour Necrosis Factor-Î± (Cachectin) and Interleukin-1. Clinical Science, 1989, 77, 357-364.	4.3	129
28	Tumour necrosis factor-Î± increases the ubiquitinization of rat skeletal muscle proteins. FEBS Letters, 1993, 323, 211-214.	2.8	125
29	Journey from cachexia to obesity by TNF. FASEB Journal, 1997, 11, 743-751.	0.5	123
30	Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Letters, 1994, 338, 311-318.	2.8	120
31	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 37-43.	7.3	115
32	Cytokines in the pathogenesis of cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 401-406.	2.5	114
33	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2005, 579, 1646-1652.	2.8	109
34	Myostatin: more than just a regulator of muscle mass. Drug Discovery Today, 2012, 17, 702-709.	6.4	105
35	Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Molecular and Cellular Endocrinology, 1998, 142, 183-189.	3.2	104
36	Cancer cachexia: the molecular mechanisms. International Journal of Biochemistry and Cell Biology, 2003, 35, 405-409.	2.8	102

#	Article	IF	Citations
37	Are there any benefits of exercise training in cancer cachexia?. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 73-76.	7.3	102
38	Muscle wasting associated with cancer cachexia is linked to an important activation of the atp-dependent ubiquitin-mediated proteolysis. International Journal of Cancer, 1995, 61, 138-141.	5.1	101
39	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Letters, 1998, 133, 83-87.	7.2	98
40	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2004, 569, 201-206.	2.8	95
41	DNA Fragmentation Occurs in Skeletal Muscle during Tumor Growth: A Link with Cancer Cachexia?. Biochemical and Biophysical Research Communications, 2000, 270, 533-537.	2.1	94
42	The role of uncoupling proteins in pathophysiological states. Biochemical and Biophysical Research Communications, 2002, 293, 1145-1152.	2.1	90
43	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 2036-2046.	2.8	89
44	In the rat, tumor necrosis factor Î± administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. FEBS Letters, 1998, 440, 348-350.	2.8	88
45	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Letters, 2001, 167, 33-38.	7.2	88
46	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 2002, 1570, 33-37.	2.4	87
47	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition, 2005, 21, 977-985.	2.4	86
48	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2770-2778.	2.4	83
49	Effects of Eicosapentaenoic Acid (EPA) Treatment on Insulin Sensitivity in an Animal Model of Diabetes: Improvement of the Inflammatory Status. Obesity, 2011, 19, 362-369.	3.0	80
50	Interleukin-15 increases glucose uptake in skeletal muscle An antidiabetogenic effect of the cytokine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1613-1617.	2.4	79
51	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. International Journal of Oncology, 2013, 43, 886-894.	3.3	79
52	Central Melanin-Concentrating Hormone Influences Liver and Adipose Metabolism Via Specific Hypothalamic Nuclei and Efferent Autonomic/JNK1 Pathways. Gastroenterology, 2013, 144, 636-649.e6.	1.3	79
53	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget, 2015, 6, 43202-43215.	1.8	78
54	The role of cytokines in muscle wasting: Its relation with cancer cachexia. Medicinal Research Reviews, 1992, 12, 637-652.	10.5	77

#	Article	IF	Citations
55	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 95-104.	7.3	72
56	Cachexia: a problem of energetic inefficiency. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 279-286.	7.3	72
57	Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. Antioxidants and Redox Signaling, 2010, 12, 365-380.	5.4	71
58	Anti-Tumour Necrosis Factor-Î± Treatment Interferes with Changes in Lipid Metabolism in a Tumour Cachexia Model. Clinical Science, 1994, 87, 349-355.	4.3	70
59	Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. International Journal of Molecular Medicine, 2011, 27, 15-24.	4.0	70
60	Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Letters, 1998, 130, 19-27.	7.2	69
61	Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function. Journal of Molecular Biology, 2019, 431, 2674-2686.	4.2	69
62	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Letters, 2007, 245, 144-148.	7.2	68
63	The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends in Pharmacological Sciences, 1996, 17, 223-226.	8.7	67
64	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Letters, 1998, 436, 415-418.	2.8	64
65	Anti-inflammatory therapies in cancer cachexia. European Journal of Pharmacology, 2011, 668, S81-S86.	3.5	63
66	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discovery Today, 2009, 14, 208-213.	6.4	61
67	Catabolic proinflammatory cytokines. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 245-251.	2.5	61
68	Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncology Reports, 2005, 14, 257-63.	2.6	61
69	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. Journal of Cellular Physiology, 2000, 184, 380-384.	4.1	60
70	Novel approaches to the treatment of cachexia. Drug Discovery Today, 2008, 13, 73-78.	6.4	60
71	Counteracting Inflammation: A Promising Therapy in Cachexia. Critical Reviews in Oncogenesis, 2012, 17, 253-262.	0.4	59
72	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clinical Nutrition, 2007, 26, 614-618.	5.0	58

#	Article	IF	Citations
73	Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario. Seminars in Cell and Developmental Biology, 2016, 54, 20-27.	5.0	58
74	Optimal management of cancer anorexia–cachexia syndrome. Cancer Management and Research, 2010, 2, 27.	1.9	57
75	Muscle wasting in cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 221-225.	2.5	56
76	Tumor necrosis factor-Î± exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1542, 66-72.	4.1	55
77	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <scp>II</scp> receptor inhibition and Î²â€2 agonist. International Journal of Cancer, 2016, 138, 2021-2029.	5.1	55
78	Novel targeted therapies for cancer cachexia. Biochemical Journal, 2017, 474, 2663-2678.	3.7	55
79	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. International Journal of Molecular Medicine, 2005, 16, 471-6.	4.0	54
80	Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Letters, 1995, 95, 33-38.	7.2	52
81	Training Depletes Muscle Glutathione in Patients with Chronic Obstructive Pulmonary Disease and Low Body Mass Index. Respiration, 2006, 73, 757-761.	2.6	52
82	Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. International Journal of Cancer, 2012, 131, 2187-2196.	5.1	51
83	Effects of interleukin-15 on lipid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 37-42.	2.4	50
84	Cytokines as Mediators and Targets for Cancer Cachexia. Cancer Treatment and Research, 2006, 130, 199-217.	0.5	50
85	Mediators of cachexia in cancer patients. Nutrition, 2019, 66, 11-15.	2.4	50
86	Interleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Letters, 1994, 76, 1-4.	7.2	48
87	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. FEBS Letters, 2005, 579, 717-722.	2.8	48
88	Conversion of leucine to Î²-hydroxy-Î²-methylbutyrate by Î±-keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 68-78.	7.3	48
89	Potassium Channels are a New Target Field in Anticancer Drug Design. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 212-223.	1.6	46
90	Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. Frontiers in Physiology, 2017, 8, 92.	2.8	46

#	Article	IF	Citations
91	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 48-59.	7.3	45
92	Comparative effects of Î²2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Letters, 1997, 115, 113-118.	7.2	44
93	Mechanisms and treatment of cancer cachexia. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, S19-S24.	2.6	44
94	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 315-320.	7.3	44
95	Therapeutic strategies against cancer cachexia. European Journal of Translational Myology, 2019, 29, 7960.	1.7	44
96	Catabolic mediators as targets for cancer cachexia. Drug Discovery Today, 2003, 8, 838-844.	6.4	43
97	Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of Î²2-Adrenergic Agonists. Cancer Research, 2007, 67, 6512-6519.	0.9	43
98	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. International Journal of Biochemistry and Cell Biology, 2008, 40, 1674-1678.	2.8	43
99	Nonmuscle Tissues Contribution to Cancer Cachexia. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	43
100	Mechanisms to explain wasting of muscle and fat in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2007, 1, 293-298.	1.3	42
101	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clinical Nutrition, 2007, 26, 239-244.	5.0	42
102	Leptin and tumor growth in rats. , 1999, 81, 726-729.		41
103	Accounting information and the prediction of farm non-viability. European Accounting Review, 2001, 10, 73-105.	3.8	41
104	The use of financial accounting information and firm performance: an empirical quantification for farms. Accounting and Business Research, 2003, 33, 251-273.	1.8	41
105	The Pharmacological Treatment of Cachexia. Current Drug Targets, 2004, 5, 265-277.	2.1	41
106	Effects of ILâ€15 on Rat Brown Adipose Tissue: Uncoupling Proteins and PPARs. Obesity, 2008, 16, 285-289.	3.0	40
107	Effects of the beta 2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. Biochimie, 2018, 149, 79-91.	2.6	39
108	Branched-chain amino acids: A role in skeletal muscle proteolysis in catabolic states?. Journal of Cellular Physiology, 2002, 191, 283-289.	4.1	38

#	Article	IF	Citations
109	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 1609-1619.	2.8	38
110	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine, 2003, 22, 1-4.	3.2	37
111	l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clinical Nutrition, 2012, 31, 889-895.	5.0	37
112	A new look at an old drug for the treatment of cancer cachexia: Megestrol acetate. Clinical Nutrition, 2013, 32, 319-324.	5.0	37
113	The potential of ghrelin in the treatment of cancer cachexia. Expert Opinion on Biological Therapy, 2013, 13, 67-76.	3.1	35
114	Roles of Skeletal Muscle and Peroxisome Proliferator-Activated Receptors in the Development and Treatment of Obesity. Endocrine Reviews, 2006, 27, 318-329.	20.1	34
115	TNF-Î± modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Letters, 2002, 175, 181-185.	7.2	33
116	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. FEBS Letters, 2009, 583, 350-356.	2.8	33
117	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncology Reports, 2011, 25, 189-93.	2.6	33
118	Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Letters, 1996, 99, 7-14.	7.2	32
119	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. Journal of Nutritional Biochemistry, 2000, 11, 431-435.	4.2	31
120	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncology Letters, 2012, 3, 185-189.	1.8	31
121	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. FEBS Letters, 2001, 505, 255-258.	2.8	29
122	Antiproteolytic effects of plasma from hibernating bears: A new approach for muscle wasting therapy?. Clinical Nutrition, 2007, 26, 658-661.	5.0	29
123	Lipid metabolism in tumour-bearing mice:. Molecular and Cellular Endocrinology, 1997, 132, 93-99.	3.2	27
124	Short-term effects of leptin on lipid metabolism in the rat. FEBS Letters, 1998, 431, 371-374.	2.8	27
125	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. Clinical Nutrition, 2010, 29, 733-737.	5.0	27
126	The systemic inflammatory response is involved in the regulation of K+channel expression in brain via TNF-Î±-dependent and -independent pathways. FEBS Letters, 2004, 572, 189-194.	2.8	26

#	Article	IF	Citations
127	The AP-1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia. FEBS Letters, 2006, 580, 691-696.	2.8	26
128	Interleukinâ€15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. Lipids, 2011, 46, 1033-1042.	1.7	25
129	Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Letters, 1995, 91, 73-78.	7.2	24
130	Controversy in Basic Sciences Is TNF Really Involved in Cachexia?. Cancer Investigation, 1997, 15, 47-54.	1.3	24
131	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	2.5	24
132	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor-Î±?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2001, 1499, 249-256.	4.1	23
133	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: Possible involvement on in vivo adipocyte differentiation. International Journal of Molecular Medicine, 2009, 24, 453-8.	4.0	23
134	Hypothalamic food intake regulation in a cancerâ€cachectic mouse model. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 159-169.	7.3	23
135	Sirtuin 1 in skeletal muscle of cachectic tumourâ€bearing rats: a role in impaired regeneration?. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 57-62.	7.3	22
136	The 2015 ESPEN Sir David Cuthbertson lecture: Inflammation as the driving force of muscle wasting in cancer. Clinical Nutrition, 2017, 36, 798-803.	5.0	22
137	Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Letters, 1995, 97, 25-32.	7.2	21
138	Metabolic interrelationships between liver and skeletal muscle in pathological states. Life Sciences, 2001, 69, 1345-1361.	4.3	21
139	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle and Nerve, 2008, 37, 190-195.	2.2	21
140	Lipopolysaccharide (LPS) increases thein vivo oxidation of branched-chain amino acids in the rat: A cytokine-mediated effect. Molecular and Cellular Biochemistry, 1995, 148, 9-15.	3.1	20
141	Impaired voltage-gated K+channel expression in brain during experimental cancer cachexia. FEBS Letters, 2003, 536, 45-50.	2.8	20
142	Fair value versus historical cost-based valuation for biological assets: predictability of financial information. Revista De Contabilidad-Spanish Accounting Review, 2011, 14, 87-113.	0.9	20
143	A differential pattern of gene expression in skeletal muscle of tumorâ€bearing rats reveals dysregulation of excitationâ€“contraction coupling together with additional muscle alterations. Muscle and Nerve, 2014, 49, 233-248.	2.2	20
144	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. PeerJ, 2017, 5, e4109.	2.0	20

#	Article	IF	Citations
145	Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Molecular and Cellular Biochemistry, 1996, 165, 17-23.	3.1	18
146	Targets in clinical oncology: the metabolic environment of the patient. Frontiers in Bioscience - Landmark, 2007, 12, 3024.	3.0	18
147	Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutrition and Metabolism, 2012, 9, 76.	3.0	18
148	The Three Faces of Sarcopenia. Journal of the American Medical Directors Association, 2016, 17, 471-472.	2.5	18
149	Cancer cachexia, a clinical challenge. Current Opinion in Oncology, 2019, 31, 286-290.	2.4	18
150	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Letters, 2003, 200, 153-160.	7.2	17
151	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. Journal of Lipid Research, 2013, 54, 3045-3051.	4.2	17
152	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. Frontiers in Physiology, 2017, 8, 184.	2.8	17
153	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: A role in muscle wasting?. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 253-258.	2.4	16
154	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. Experimental and Therapeutic Medicine, 2011, 2, 731-735.	1.8	16
155	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia. , 2011, , 9-35.		16
156	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 2007, 30, 1239-45.	3.3	15
157	A flow cytometric study of the rat Yoshida AH-130 ascites hepatoma. Cancer Letters, 1993, 72, 169-173.	7.2	13
158	Accounting Research: A Critical View Of The Present Situation And Prospects. Revista De Contabilidad-Spanish Accounting Review, 2011, 14, 9-34.	0.9	13
159	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817-9.	4.0	13
160	Sepsis induces DNA fragmentation in rat skeletal muscle. European Cytokine Network, 2003, 14, 256-9.	2.0	12
161	Sequential changes in lipoprotein lipase activity and lipaemia induced by the Yoshida AH-130 ascites hepatoma in rats. Cancer Letters, 1997, 116, 159-165.	7.2	11
162	Metabolic effects of tumour necrosis factor-Î± on rat brown adipose tissue. Molecular and Cellular Biochemistry, 1995, 143, 113-118.	3.1	10

#	Article	IF	Citations
163	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. Clinical Nutrition, 2011, 30, 33-37.	5.0	10
164	Unifying diagnostic criteria for cachexia: An urgent need. Clinical Nutrition, 2017, 36, 910-911.	5.0	10
165	Differential structural features in soleus and gastrocnemius of carnitineâ€treated cancer cachectic rats. Journal of Cellular Physiology, 2020, 235, 526-537.	4.1	10
166	Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 1994, 87, 123-130.	7.2	9
167	Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1028-1036.	2.4	9
168	Protein breakdown on whole-body and organ level in non-cachectic tumour-bearing mice undergoing surgery. Clinical Nutrition, 2007, 26, 483-490.	5.0	9
169	The animal cachexia score (ACASCO). Animal Models and Experimental Medicine, 2019, 2, 201-209.	3.3	9
170	Formoterol May Activate Rat Muscle Regeneration During Cancer Cachexia. Insciences Journal, 0, , 1-17.	0.7	9
171	Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma. Anticancer Research, 2009, 29, 1315-7.	1.1	9
172	The ubiquitin system: A role in disease?. , 1997, 17, 139-161.		8
173	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963-7.	4.0	8
174	Emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs, 2007, 12, 555-570.	2.4	7
175	The Role of Cytokines in Cancer Cachexia. , 2006, , 467-475.		5
176	Patterns of gene expression in muscle and fat in tumorâ€bearing rats: Effects of CRF2R agonist on cachexia. Muscle and Nerve, 2010, 42, 936-949.	2.2	5
177	Effects of formoterol on protein metabolism in myotubes during hyperthermia. Muscle and Nerve, 2011, 43, 268-273.	2.2	5
178	Omegaâ€3 and omegaâ€3/curcuminâ€enriched fruit juices decrease tumour growth and reduce muscle wasting in tumourâ€bearing mice. JCSM Rapid Communications, 2018, 1, 1-10.	1.6	5
179	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. E-SPEN Journal, 2012, 7, e135-e138.	0.5	3
180	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. JCSM Rapid Communications, 2018, 1, 1-15.	1.6	3

#	Article	IF	Citations
181	Marked hyperlipidaemia in rats bearing the Yoshida AH-130 ascites hepatoma. Biochemical Society Transactions, 1995, 23, 492S-492S.	3.4	2
182	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. International Journal of Molecular Medicine, 2004, 14, 719.	4.0	2
183	Cancer Cachexia and Fat Metabolism. , 2006, , 459-466.		2
184	Open source in cachexia?. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 112-113.	7.3	2
185	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2002, 188, 53-58.	7.2	1
186	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. ChemInform, 2005, 36, no.	0.0	1
187	Lack of Synergy Between Î²-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. OncoTargets and Therapy, 2021, Volume 14, 1953-1959.	2.0	1
188	Recent Developments in Treatment of Cachexia. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 259-273.	0.6	1
189	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
190	The assessment of productivity in biomedical research. Annals of Medicine, 2016, 48, 631-633.	3.8	0
191	Nutrition and cachexia. , 2012, , 185-194.		0